ATRenew to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

SHANGHAI,Feb. 25,2025-- ATRenew Inc. ("ATRenew" or the "Company") (NYSE: RERE),a leading technology-driven pre-owned consumer electronics transactions and services platform in Chin

India's Bharti Airtel partners Ericsson 5G Core technology to drive 5G evolution

New agreement spans packet core,signaling,charging & policy solutions STOCKHOLM,Feb. 25,2025-- India\'s Bharti Airtel and Ericsson (NASDAQ: ERIC) have strengthened their longstanding partnership t

G-P Expands Availability of G-P Gia™; Welcomes Leaders to the Next Era of HR

The smartest AI global HR advisor,G-P Gia,thinks like a lawyer and cuts the cost and time of compliance by up to 95%; reducing the need to outsource legal in 50 countries and 50 U.S. states

Baidu Acquires JOYY's Live Streaming Business in China

BEIJING,Feb. 25,2025-- Baidu,Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu"),a leading AI company with strong Internet foundation,today announced that Baid

Cedro Participações signs concession contract for the Port of Itaguaí at an event with President Lula and Minister Silvio Costa Filho

The company will be the first 100% Brazilian mining company to verticalize its operations and intends to invest R$3.6 billion in the project

GILF Shortlisted in Catalog of Guangdong's Nationwide Trade Initiative (2025), Starting New Procurement Season in March

ZHONGSHAN,China,Feb. 25,2025-- Recently,the official website of the Department of Commerce of Guangdong Province released the Catalog of Guangdong\'s Nationwide Trade Initiative (2025). After submissi

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

HONG KONG,Feb. 25,2025--Akeso,Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab,Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a c

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

SHANGHAI,Feb. 25,2025-- YolTech Therapeutics,a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines,today reported positive results fr

Yatsen Announces Fourth Quarter and Full Year 2024 Financial Results

Conference Call to Be Held at 7:30 A.M. U.S. Eastern Time on February 25,2025 GUANGZHOU,China,Feb. 25,2025--Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG),a leading

Foxit Supercharges AI Assistant with Multi-Document Analysis on iOS & Android

Enables Users to Boost Productivity with AI-Powered Summaries,Cross-Document Insights,and Instant Data Extraction Across Mobile Device